Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
Open Access
- 13 August 2014
- journal article
- retracted article
- Published by Spandidos Publications in Oncology Letters
- Vol. 8 (5) , 2043-2048
Abstract
It has previously been reported that KU60019, as a highly effective radiosensitizer, inhibits the DNA damage response and blocks radiation‑induced phosphorylation of key ataxia telangiectasia mutated targets in human glioma cells. The present study investigated whether KU60019 affects cell physiological activities and strengthens the efficacy of doxorubicin‑induced DNA damage. It was demonstrated that the compound suppressed the proliferation of MCF‑7 cells and significantly increased chemosensitization. In addition, KU60019 (without doxorubicin) inhibited MCF‑7 cell motility and invasion, potentially by acting on the phosphorylated‑Akt and E‑cadherin signaling pathways. Although the majority of MCF‑7 cells were arrested at the G1/S phase following treatment with KU60019, the combination of the two compounds did not result in such a marked effect on the cell cycle. In conclusion, KU60019 is a potent chemosensitizer in combination with doxorubicin, therefore, it may provide a promising strategy for non‑invasive breast cancer.Keywords
This publication has 22 references indexed in Scilit:
- High expression of Sonic Hedgehog signaling pathway genes indicates a risk of recurrence of breast carcinomaOncoTargets and Therapy, 2013
- An ataxia-telangiectasia-mutated (ATM) kinase mediated response to DNA damage down-regulates the mRNA-binding potential of THOC5RNA, 2011
- Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasionMolecular Cancer Therapeutics, 2009
- Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancerNature Reviews Molecular Cell Biology, 2008
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATMCancer Research, 2004
- Breast cancer: improving outcome following adjuvant radiotherapyBritish Journal of Radiology, 2004
- Regulation and mechanisms of mammalian double-strand break repairOncogene, 2003
- ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing RadiationJournal of Biological Chemistry, 2002
- Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence SpecificityMolecular Pharmacology, 1997